期刊
CELL METABOLISM
卷 19, 期 6, 页码 1034-1041出版社
CELL PRESS
DOI: 10.1016/j.cmet.2014.04.002
关键词
-
资金
- Academy of Finland
- Saastamoinen Foundation
- Finnish Cultural Foundation
- Finnish Diabetes Foundation
- NIH [R01 GM106072-01, R01HL106511-01A, R01AG043930]
- Ecole Polytechnique Federale de Lausanne
- EU [AdG-23138, AdG-322424]
- Swiss National Science Foundation [31003A-124713, 31003A-125487, CSRII3-1362]
- Medical Research Council [MC_UP_1002/1] Funding Source: researchfish
- MRC [MC_UP_1002/1] Funding Source: UKRI
- ICREA Funding Source: Custom
We previously demonstrated that the deletion of the poly(ADP-ribose) polymerase (Parp)-1 gene in mice enhances oxidative metabolism, thereby protecting against diet-induced obesity. However, the therapeutic use of PARP inhibitors to enhance mitochondrial function remains to be explored. Here, we show tight negative correlation between Parp-1 expression and energy expenditure in heterogeneous mouse populations, indicating that variations in PARP-1 activity have an impact on metabolic homeostasis. Notably, these genetic correlations can be translated into pharmacological applications. Long-term treatment with PARP inhibitors enhances fitness in mice by increasing the abundance of mitochondrial respiratory complexes and boosting mitochondrial respiratory capacity. Furthermore, PARP inhibitors reverse mitochondrial defects in primary myotubes of obese humans and attenuate genetic defects of mitochondrial metabolism in human fibroblasts and C. elegans. Overall, our work validates in worm, mouse, and human models that PARP inhibition may be used to treat both genetic and acquired muscle dysfunction linked to defective mitochondrial function.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据